Melissa Denney, NP
Family · Muncie, INNPI 1588147755
Payments from drug & device makers
Across 262 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$390
- Lilly USA, LLC$273
- Bayer$191
- Indivior Inc.$185
- Novo Nordisk$175
- plus $1K from 28 others
What the payments were for
- Food & beverage$4,155100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 129 | $1,753 |
| Amgen | 18 | $390 |
| Lilly USA, LLC | 18 | $273 |
| Bayer | 10 | $191 |
| Indivior Inc. | 11 | $185 |
| Novo Nordisk | 11 | $175 |
| Gilead | 8 | $153 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $97 |
| Otsuka America Pharmaceutical, Inc. | 4 | $85 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $82 |
| Organon | 6 | $77 |
| Pfizer | 4 | $73 |
| Axsome Therapeutics, Inc. | 3 | $59 |
| Jazz Pharmaceuticals Inc. | 3 | $53 |
| AstraZeneca | 3 | $50 |
| Mayne Pharma Commercial LLC | 2 | $47 |
| Dexcom, Inc. | 2 | $45 |
| Verona Pharma, Inc. | 2 | $44 |
| Neurocrine Biosciences, Inc. | 2 | $39 |
| Exact Sciences | 2 | $32 |
| Insulet Corporation | 1 | $24 |
| GSK | 1 | $24 |
| Noven Therapeutics, LLC | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Novartis | 1 | $18 |
| Corium, LLC | 1 | $18 |
| Tonix Medicines, Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Seqirus USA Inc | 1 | $17 |
| Tris Pharma Inc | 1 | $16 |
| Sanofi | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
How this compares
$4,155 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 109 | $112,901 |
| OzempicSemaglutide | 74 | $87,592 |
| JardianceEmpagliflozin | 132 | $82,466 |
| FarxigaDapagliflozin Propanediol | 92 | $75,353 |
| EliquisApixaban | 60 | $40,964 |
| Breo ElliptaFluticasone/Vilanterol | 64 | $32,126 |
| Spiriva HandihalerTiotropium Bromide | 33 | $25,715 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $23,601 |
| MounjaroTirzepatide | 20 | $22,086 |
| JanuviaSitagliptin Phosphate | 31 | $18,676 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 30 | $18,149 |
| LinzessLinaclotide | 31 | $18,097 |
| XareltoRivaroxaban | 21 | $17,050 |
| TradjentaLinagliptin | 19 | $15,763 |
| MyrbetriqMirabegron | 24 | $12,663 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $273 | $134,987129 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $50 | $88,422123 claims |
| Novo NordiskOzempic | $175 | $87,59274 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $24 | $68,363117 claims |
| PfizerEliquis | $73 | $40,96460 claims |
| AbbVieLinzess | $1,753 | $18,09731 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $12,66324 claims |
| NovartisEntresto | $18 | $9,17913 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $97 | $5,87112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,392 family providers in Indiana.
Other family in Muncie
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.